Biohaven Pharmaceutical (NYSE:BHVN) – Analysts at William Blair upped their Q3 2018 earnings per share estimates for shares of Biohaven Pharmaceutical in a research note issued to investors on Wednesday, May 16th. William Blair analyst T. Lugo now anticipates that the company will post earnings of ($1.09) per share for the quarter, up from their previous estimate of ($1.43). William Blair also issued estimates for Biohaven Pharmaceutical’s Q4 2018 earnings at ($1.25) EPS, FY2018 earnings at ($5.64) EPS, FY2019 earnings at ($5.01) EPS and FY2020 earnings at ($1.69) EPS.
Biohaven Pharmaceutical (NYSE:BHVN) last issued its quarterly earnings results on Tuesday, May 15th. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($1.12) by ($1.20).
Several other brokerages have also recently commented on BHVN. Zacks Investment Research cut shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. Canaccord Genuity reiterated a “buy” rating and issued a $39.00 price target (up from $30.00) on shares of Biohaven Pharmaceutical in a research report on Thursday, February 22nd. Needham & Company LLC reiterated a “buy” rating on shares of Biohaven Pharmaceutical in a research report on Thursday, February 22nd. Finally, ValuEngine upgraded shares of Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $37.29.
Shares of Biohaven Pharmaceutical opened at $30.29 on Friday, MarketBeat reports. Biohaven Pharmaceutical has a 52 week low of $29.11 and a 52 week high of $30.31.
In other Biohaven Pharmaceutical news, insider Robert Berman sold 35,000 shares of the business’s stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $30.11, for a total transaction of $1,053,850.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Kimberly Gentile sold 5,000 shares of the business’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $32.87, for a total value of $164,350.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 113,038 shares of company stock worth $3,105,100. Corporate insiders own 34.20% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc raised its holdings in Biohaven Pharmaceutical by 111.3% during the 1st quarter. Legal & General Group Plc now owns 5,626 shares of the company’s stock worth $145,000 after buying an additional 2,963 shares during the period. BNP Paribas Arbitrage SA raised its holdings in Biohaven Pharmaceutical by 189.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 6,299 shares of the company’s stock worth $162,000 after buying an additional 4,121 shares during the period. DRW Securities LLC acquired a new stake in Biohaven Pharmaceutical during the 1st quarter worth about $232,000. Endurant Capital Management LP acquired a new stake in Biohaven Pharmaceutical during the 4th quarter worth about $278,000. Finally, Jane Street Group LLC acquired a new position in shares of Biohaven Pharmaceutical in the 1st quarter valued at about $322,000. Hedge funds and other institutional investors own 63.34% of the company’s stock.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.